SYNTONIX PHARMACEUTICALS

syntonix-pharmaceuticals-logo

Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the companyโ€™s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonixโ€™ drug delivery platform technology Transceptorโ„ข, harness the bodyโ€™s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focus... es on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.

#People #Financial #Website #More

SYNTONIX PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Health Care

Founded:
1997-06-01

Address:
Waltham, Massachusetts, United States

Country:
United States

Website Url:
http://www.syntnx.com

Total Employee:
11+

Status:
Closed

Contact:
(781)547-6000

Email Addresses:
[email protected]

Total Funding:
35.8 M USD

Technology used in webpage:
CSC Global DNS



Current Advisors List

jeanne-cunicelli_image

Jeanne Cunicelli Board Member @ Syntonix Pharmaceuticals
Board_member

Current Employees Featured

not_available_image

Greg Zarbis-Papastoitsis
Greg Zarbis-Papastoitsis Associate Director of Process Development and Analytical Sciences @ Syntonix Pharmaceuticals
Associate Director of Process Development and Analytical Sciences

john-ripple_image

John Ripple
John Ripple Vice President, Corporate Development @ Syntonix Pharmaceuticals
Vice President, Corporate Development

alan-j-bitonti_image

Alan J. Bitonti
Alan J. Bitonti Vice President, Research and Development @ Syntonix Pharmaceuticals
Vice President, Research and Development
2007-01-01

Acquisitions List

Date Company Article Price
2011-05-11 Leeds Skin Leeds Skin acquired by Syntonix Pharmaceuticals 900 M GBP

Investors List

alta-partners_image

Alta Partners

Alta Partners investment in Series B - Syntonix Pharmaceuticals

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Series B - Syntonix Pharmaceuticals

a-m-pappas-associates_image

A. M. Pappas & Associates

A. M. Pappas & Associates investment in Series B - Syntonix Pharmaceuticals

venrock_image

Venrock

Venrock investment in Seed Round - Syntonix Pharmaceuticals

Official Site Inspections

http://www.syntnx.com

  • Host name: 165.160.13.20
  • IP address: 165.160.13.20
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Syntonix Pharmaceuticals" on Search Engine